Search results
Earnings call: Fate Therapeutics reports on clinical progress and finances By Investing.com
Investing.com· 2 days agoThe company's FT819 CAR T-cell therapy showed promise for B-cell-mediated autoimmune diseases, with...
Earnings call: Fate Therapeutics reports on clinical progress and finances
Investing.com· 3 days agoThe company's FT819 CAR T-cell therapy showed promise for B-cell-mediated autoimmune diseases, with...
...on Successful Use of Applied DNA’s Linea DNATM for the Non-Viral Manufacture of CAR T-Cell ...
The Kansas City Star· 2 days agoAccepted abstracts...
This time, it's personal: Enhancing patient response to cancer immunotherapy
Medical Xpress· 5 hours agoRecently, scientists have noticed that patients whose tumors have a mutation in a gene called ARID1A are more likely to respond positively to immune checkpoint blockade, a type of immunotherapy ...
US FDA approves expanded use of Bristol Myers' cancer cell therapy
AOL· 3 hours agoThe Food and Drug Administration's decision marks the fourth approval for Breyanzi. It was first approved in the United States in 2021 as a second-line treatment for a type of blood cancer known as large B-cell lymphoma.
Regeneron's cell medicines chief is crafting a new cell therapy 'secret sauce'
FierceBiotech· 7 days agoNow head of Regeneron Cell Medicines, Gregory came over to the famed Big Biotech with the sale of...
Adaptimmune secures $125 million loan for cancer therapy By Investing.com
Investing.com· 7 hours agoAdaptimmune Therapeutics plc (NASDAQ: NASDAQ:ADAP), a biopharmaceutical firm specializing in cell ...
Cytiva: 'BIO is a very important convention for us'
BioPharma-Reporter· 11 hours agoLife sciences business Cytiva is set to launch its new platform, designed to accelerate the manufacturing process for autologous CAR-T cell therapies....
Acepodia reports preliminary results from ACE1831 Phase I trial
Clinical Trials Arena via Yahoo Finance· 7 days agoClinical-stage biotechnology company Acepodia has reported preliminary results from the Phase I...
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Fontana Herald News· 1 day ago"We continue to build momentum in the clinical development of our lead product candidate, KYV-101, as we seek to bring autoimmune CAR T-cell therapies to ...